EW vs. INCY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EW and INCY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Symbol | EW | INCY |
---|---|---|
Company Name | Edwards Lifesciences Corporation | Incyte Corporation |
Country | United States | United States |
GICS Sector | Health Care | Health Care |
GICS Industry | Health Care Equipment & Supplies | Biotechnology |
Market Capitalization | 44.47 billion USD | 16.67 billion USD |
Exchange | NYSE | NasdaqGS |
Listing Date | March 27, 2000 | November 4, 1993 |
Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EW and INCY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
Symbol | EW | INCY |
---|---|---|
5-Day Price Return | -1.19% | -1.04% |
13-Week Price Return | -1.88% | 24.24% |
26-Week Price Return | 3.78% | 36.70% |
52-Week Price Return | 17.35% | 29.84% |
Month-to-Date Return | -2.61% | 0.67% |
Year-to-Date Return | 2.31% | 23.61% |
10-Day Avg. Volume | 4.54M | 1.52M |
3-Month Avg. Volume | 4.23M | 1.82M |
3-Month Volatility | 20.42% | 32.66% |
Beta | 0.96 | 0.82 |
Profitability
Return on Equity (TTM)
EW
41.25%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
EW’s Return on Equity of 41.25% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
INCY
24.09%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 24.09% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
EW
72.96%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
EW’s Net Profit Margin of 72.96% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
INCY
18.99%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 18.99% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EW
25.01%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
An Operating Profit Margin of 25.01% places EW in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
INCY
25.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 25.80% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
Symbol | EW | INCY |
---|---|---|
Return on Equity (TTM) | 41.25% | 24.09% |
Return on Assets (TTM) | 31.58% | 15.81% |
Net Profit Margin (TTM) | 72.96% | 18.99% |
Operating Profit Margin (TTM) | 25.01% | 25.80% |
Gross Profit Margin (TTM) | 78.87% | 93.41% |
Financial Strength
Current Ratio (MRQ)
EW
4.68
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
EW’s Current Ratio of 4.68 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
INCY
2.85
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
INCY’s Current Ratio of 2.85 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EW
0.06
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, EW’s Debt-to-Equity Ratio of 0.06 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
INCY
0.01
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EW
3.15
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
In the lower quartile for the Health Care Equipment & Supplies industry, EW’s Interest Coverage Ratio of 3.15 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
Symbol | EW | INCY |
---|---|---|
Current Ratio (MRQ) | 4.68 | 2.85 |
Quick Ratio (MRQ) | 3.79 | 2.55 |
Debt-to-Equity Ratio (MRQ) | 0.06 | 0.01 |
Interest Coverage Ratio (TTM) | 3.15 | 6.86 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EW
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
EW currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EW
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
EW has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
Symbol | EW | INCY |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EW
10.63
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
EW’s P/E Ratio of 10.63 is below the typical range for the Health Care Equipment & Supplies industry. This may indicate that the stock is potentially undervalued, or it could reflect market concerns about the company’s future prospects.
INCY
19.17
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
INCY’s P/E Ratio of 19.17 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
EW
7.75
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
EW’s P/S Ratio of 7.75 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
INCY
3.64
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.64 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
EW
4.35
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
EW’s P/B Ratio of 4.35 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
INCY
3.16
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
INCY’s P/B Ratio of 3.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
Symbol | EW | INCY |
---|---|---|
Price-to-Earnings Ratio (TTM) | 10.63 | 19.17 |
Price-to-Sales Ratio (TTM) | 7.75 | 3.64 |
Price-to-Book Ratio (MRQ) | 4.35 | 3.16 |
Price-to-Free Cash Flow Ratio (TTM) | 58.01 | 17.42 |